TABLE 4.
Outcome measuresf | Pre-first treatmenta | Post-first treatmentb | Pre-second treatmentc | Post-second treatmentd | Post-third treatmente |
---|---|---|---|---|---|
I. Motor evaluation total score | 14 | 11 | 12 | 4 | 3 |
II. Complications of therapy total score | 9 | 1 | 5 | 1 | 0 |
III. Mental total score | 1 | 0 | 0 | 0 | 0 |
IV. Activities of daily living total score | 10 | 4 | 5 | 0 | 0 |
V. Hoehn & Yahr stagingsg | 3 | 2 | 2 | 2 | 2 |
VI. Scoring of motor fluctuationsh | C | A | B | A | A |
SF-36 subscalesf | |||||
General health | 55 | 87 | — | 72 | 77 |
Physical functioning | 45 | 55 | — | 65 | 80 |
Role-physical (RP) | 25 | 75 | — | 75 | 100 |
Vitality | 40 | 45 | — | 30 | 55 |
Physical summary | 34.48 | 43.48 | — | 43.82 | 52.18 |
On first admission to the Center for Chronic Disorders (CCD).
6 weeks after first CCD program.
On second admission to CCD.
2 weeks after second CCD program.
6 weeks after third CCD program.
I-VI are from Rabey et al. Evaluation of the Short Parkinson’s Evaluation Scale: A new friendly scale for the evaluation of Parkinson’s disease in clinical drug trials. Clinical Neuropharmacology.1997;20:322–337. Except for V and VI, scores for individual items ranged from 0 (no disease) to 3 (severest disease).
0 = no signs of disease; 1 = unilateral disease; 2 = bilateral disease; 3 = some postural instability, mild-moderate bilateral disease, physically independent; 4 = severe disability but still able to walk or stand unassisted; 5 = wheelchair bound or bedridden unless aided.
A = no motor fluctuations or dyskinesias; B = dyskinesias and/or akinetic episodes and/or freezing gait that affect daily life; C = dyskinesias and/or akinetic episodes and/or freezing episodes that affect daily activities; D = dyskinesias and/or akinetic episodes and/or freezing gait that significantly affect activities of daily life; require considerable assistance for activities of daily life.